(AMPH) Amphastar Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AMPH) Amphastar Pharmaceuticals, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This Amphastar Pharmaceuticals, Inc. BCG Matrix helps you see how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and portfolio review. The page already includes a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Primatene Mist, 1 FDA-approved OTC epinephrine inhaler
Primatene Mist is Amphastar Pharmaceuticals, Inc.’s clearest branded leader: it is the only FDA-approved OTC epinephrine inhaler for temporary relief of mild asthma symptoms. That first-mover slot gives it a rare consumer rescue-category position, with U.S. asthma affecting about 28 million people and OTC respiratory demand staying resilient. Its scale and brand recognition make it a strong Star candidate in a growing OTC niche.
Naloxone injection and prefilled syringe, opioid-overdose reversal
Demand for naloxone stays high because it is the core rescue drug for opioid overdose; the CDC said the U.S. still had about 105,000 drug overdose deaths in 2023. Amphastar Pharmaceuticals, Inc. serves hospitals and public-health channels in a growing emergency market, so this product fits a Star if share stays strong.
Glucagon emergency kits, severe hypoglycemia treatment
Glucagon emergency kits fit a Stars slot because severe hypoglycemia is acute, repeat-use care, and diabetes demand stays steady. Amphastar reported 2025 net revenues of $722.9 million, with injectables still central to the mix, so this franchise can scale with hospital stocking and refill demand.
Epinephrine injections, severe allergic reaction treatment
Epinephrine injections stay a life-saving hospital and emergency product, with steady demand from anaphylaxis care and crash carts. Amphastar Pharmaceuticals, Inc.’s injectable manufacturing base supports repeat ordering and wide placement, which fits a Star in specialty injectables.
The product’s scale and visibility matter: in 2025, Amphastar reported total net revenues of $____, and its injectable portfolio continued to anchor pharmacy and hospital use. That kind of recurring demand and distribution reach is what keeps epinephrine in the Star bucket.
- Constant emergency demand
- Repeat hospital ordering
- Broad injectable placement
- Strong specialty visibility
Sterile injectables platform, hospital-use products
Amphastar Pharmaceuticals, Inc.'s sterile injectable platform is a true Star because it anchors hospital-use therapies and can scale across emergency and inpatient care. The same manufacturing base supports both branded and generic launches, which helps keep the pipeline active and revenue spread across multiple critical products. Sterile injectables are hard to copy, so this platform stays strategically valuable.
- Drives hospital-critical demand
- Supports branded and generic launches
- Uses a hard-to-replicate sterile base
Amphastar’s Star Products Power Its Injectable Growth
Stars in Amphastar Pharmaceuticals, Inc. are the products with strong demand and high visibility: Primatene Mist, naloxone, glucagon, and epinephrine injections. In 2025, Amphastar Pharmaceuticals, Inc. reported net revenues of $722.9 million, showing the scale behind its injectable-led franchise. These products fit a Star profile because they serve urgent, repeat-use care in large, durable markets.
| Product | 2025 signal | Star fit |
|---|---|---|
| Primatene Mist | Only FDA-approved OTC epinephrine inhaler | Branded rescue leader |
| Naloxone | Supports overdose response demand | High-need emergency use |
| Glucagon | Hypoglycemia rescue therapy | Recurring hospital stock |
| Epinephrine injections | Crash-cart staple | Broad inpatient use |
What is included in the product
Detailed Word Document
Amphastar Pharmaceuticals’ BCG Matrix maps its portfolio into stars, cash cows, question marks, and dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page BCG view for Amphastar Pharmaceuticals, Inc., clarifying business unit priorities at a glance
Reference Sources
Provides traceable sources behind Amphastar Pharmaceuticals, Inc. claims, boosting credibility and speeding confident decision-making.
Cash Cows
Enoxaparin injection, low-molecular-weight heparin
Enoxaparin injection is a mature generic low-molecular-weight heparin with steady hospital and institutional demand, so it fits the Cash Cow bucket. In a low-growth anticoagulant market, Amphastar Pharmaceuticals, Inc. benefits from established supply, repeat inpatient use, and entrenched purchasing patterns. That makes this line more about harvesting cash than chasing growth.
Lidocaine products, jelly and topical solution
Lidocaine jelly and topical solution are a classic cash cow for Amphastar Pharmaceuticals, Inc.: mature, low-growth, and used across routine procedures in hospitals and clinics. Demand is steady, not flashy, but the long-standing brand family and broad clinical use keep cash flow reliable even as growth stays limited.
Lorazepam injection, surgical and medical procedures
Lorazepam injection is a long-established hospital drug used for seizure control, sedation, and pre-op care, so demand is steady and tied to inpatient procedures. Its market is mature, so Amphastar Pharmaceuticals, Inc. usually does not need heavy promotion to keep volume. That makes it a classic Cash Cow: stable sales, limited marketing spend, and strong cash generation.
Morphine injection, patient-controlled analgesia
Morphine injection for patient-controlled analgesia is a mature hospital analgesic with repeat inpatient use, so it behaves like a cash cow: low growth, steady demand, and reliable volume capture. Amphastar Pharmaceuticals, Inc. has not disclosed a separate 2025 sales figure for this line, but the product still helps convert established hospital accounts into recurring cash flow.
- Legacy inpatient use
- Low-growth category
- Recurring hospital demand
- Cash-generating volume
Phytonadione injection, Vitamin K1
Phytonadione injection (Vitamin K1) fits a Cash Cow at Amphastar Pharmaceuticals, Inc. because it serves a narrow, recurring hospital need, especially newborn prophylaxis, so demand stays steady rather than fast-growing. The use case is routine and low-volatility, which supports reliable sales without heavy growth spending.
- Stable newborn hospital demand
- Routine, well-defined use case
- Low-growth, high-visibility revenue
Amphastar’s Cash Cows: Steady Hospital Demand, Not Fast Growth
Amphastar Pharmaceuticals, Inc.’s Cash Cows are mature hospital injectables with steady repeat use, not fast growth. Enoxaparin, lidocaine, lorazepam, morphine, and phytonadione support recurring inpatient demand and low-marketing cash flow. Amphastar Pharmaceuticals, Inc. has not disclosed 2025 sales for each line here, so the key signal is stable volume, not expansion.
| Product | Role | Signal |
|---|---|---|
| Enoxaparin | Cash Cow | Steady hospital use |
| Lidocaine | Cash Cow | Routine procedures |
Get Your Copy
Amphastar Pharmaceuticals, Inc. Reference Sources
The Amphastar Pharmaceuticals, Inc. BCG Matrix preview you’re seeing is the exact same file you’ll receive after purchase. No demo pages, no watermarks—just the full, ready-to-use report. Once purchased, the document is instantly available for your strategic analysis, presentation, or internal planning.
Dogs
Amphadase, bovine hyaluronidase injection
Amphadase, bovine hyaluronidase injection, fits the Dog quadrant because it is a niche legacy product with limited scale and no clear path to become a major growth driver in Amphastar Pharmaceuticals, Inc.'s 2025 portfolio. Its market is small, and growth looks modest versus the company’s larger injectable and specialty products. In BCG terms, it likely ties up little capital but also adds little upside.
Cortrosyn, diagnostic agent for adrenocortical insufficiency
Cortrosyn is a niche ACTH diagnostic with a narrow test base, so it has limited volume and weak growth leverage. In a mature, concentrated market, that usually means low pricing power and modest expansion for Amphastar Pharmaceuticals, Inc. Its small, specialist role fits Dog territory in the BCG Matrix.
Neostigmine methylsulfate injection, muscle-relaxant reversal
Neostigmine methylsulfate injection is a narrow anesthesia-reversal product used after surgery to reverse nondepolarizing neuromuscular blockade. That makes its addressable market small and tied to operating-room volume, not broad chronic demand. For Amphastar Pharmaceuticals, Inc., this fits a Dog: low share, low growth, and limited room to expand.
Isoproterenol hydrochloride injection, transient heart block use
Isoproterenol hydrochloride injection is a highly specialized hospital-only product, so demand is episodic and tied to rare transient heart block cases. That makes scale limited and growth hard to sustain, which fits a Dog in Amphastar Pharmaceuticals, Inc.'s BCG matrix.
- Hospital use only
- Low, irregular demand
- Weak scale economics
- Dog-type asset
Porcine insulin API, legacy insulin supply
Porcine insulin API is a niche, legacy supply line for Amphastar Pharmaceuticals, Inc., not a growth driver. It serves a narrow channel, not a broad branded market, so it stays in Dog territory. Amphastar’s 2024 net revenues were about $733.8 million, yet this older insulin API remains a small, low-priority piece of the mix.
- Low market share
- Limited demand pool
- Legacy supply only
- Weak growth profile
Amphastar’s Dog Products Stay Small and Slow-Growing
Amphastar Pharmaceuticals, Inc.'s Dogs are low-share, low-growth niche products that add little to 2025 growth. Amphadase, Cortrosyn, neostigmine methylsulfate, isoproterenol, and porcine insulin API stay small because demand is narrow, episodic, or legacy-based. They fit a harvest-or-maintain role, not a scale-up bet.
| Product | BCG | Signal |
|---|---|---|
| Amphadase | Dog | Legacy niche |
| Cortrosyn | Dog | Small test base |
Question Marks
Recombinant human insulin API, API distribution
Recombinant human insulin API and API distribution fit Question Mark status: the segment sits in a large, still-growing insulin supply chain, but Amphastar Pharmaceuticals, Inc. is not the clear leader. Large insulin makers still control most branded volume, so Amphastar’s share looks limited even if demand for reliable API supply stays solid. That mix of upside and weak share is classic Question Mark territory.
Active Pharmaceutical Ingredients segment, limited branded visibility
Amphastar Pharmaceuticals, Inc.’s Active Pharmaceutical Ingredients unit fits a Question Mark: API demand can grow, but it lacks Primatene Mist’s brand pull. In FY2025, the company still relied more on branded respiratory products for margin support, while API stayed a smaller, more price-pressed business. Larger global API suppliers make share harder to defend, so the unit needs focused investment or selective pruning.
China commercial channel, 1 of Amphastar’s 3 markets
Amphastar Pharmaceuticals, Inc. posted $672.9 million in net revenues in 2024, yet China is still a small part of its commercial footprint. The market is huge, but local competition and pricing pressure are intense, so China fits a Question Mark role: high upside, low current share, and a real need for capital to scale.
France commercial channel, international footprint
France gives Amphastar Pharmaceuticals, Inc. a 68 million-person market and lowers U.S. concentration risk, but it is still not a scale driver. The channel can grow, yet limited share means returns are still uncertain, so it fits a Question Mark in BCG terms: invest to build, or exit if share does not improve.
- Geographic diversification, not core scale
- Growth upside, but low market share
- Needs investment to win share
- Else, weak fit for capital
Future intranasal follow-on products, beyond Primatene Mist
Amphastar Pharmaceuticals, Inc. has real intranasal know-how, but its follow-on products still lack clear market leadership, so this fits a Question Mark. Primatene Mist is still the only FDA-approved OTC epinephrine inhaler, while newer intranasal bets need adoption to turn category growth into share.
- High know-how, weak share
- Growth depends on adoption
- Leadership is not proven yet
Amphastar’s Growth Bets Show Promise, but Scale Still Lags
Amphastar Pharmaceuticals, Inc.’s Question Marks have growth potential, but they still lack scale and share. API and China can expand, yet both face heavy competition and pricing pressure. France adds diversification, but it is not yet a real growth engine. In 2024, Amphastar Pharmaceuticals, Inc. generated $672.9 million in net revenues, so these bets need selective investment, not broad spending.
| Area | Signal |
|---|---|
| API | Growth, low share |
| China | Large market, weak position |
| France | Diversifies, not core scale |
| 2024 revenue | $672.9 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.